Diminished nuclear-localized β-adrenoceptor signalling activates YAP to promote kidney fibrosis in diabetic nephropathy.

IF 6.8 2区 医学 Q1 PHARMACOLOGY & PHARMACY
Wenjing Xiang, Lei Li, Manman Qin, Lei Li, Hualong Yu, Fangyuan Wang, Siyuan Ni, Ao Shen, Haocheng Lu, Haibo Ni, Ying Wang
{"title":"Diminished nuclear-localized β-adrenoceptor signalling activates YAP to promote kidney fibrosis in diabetic nephropathy.","authors":"Wenjing Xiang, Lei Li, Manman Qin, Lei Li, Hualong Yu, Fangyuan Wang, Siyuan Ni, Ao Shen, Haocheng Lu, Haibo Ni, Ying Wang","doi":"10.1111/bph.17347","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and purpose: </strong>Diabetic nephropathy (DN) is a leading cause of chronic kidney disease (CKD), which is characterized by mesangial matrix expansion that involves dysfunctional mesangial cells (MCs). However, the underlying mechanisms remain unclear. This study aims to delineate the spatiotemporal contribution of adrenergic signalling in diabetic kidney fibrosis to reveal potential therapeutic targets.</p><p><strong>Experimental approach: </strong>A model of diabetic nephropathy was induced by in db/db mice. Gene expression in kidneys was profiled by RNA-seq analyses, western blot and immunostaining. Subcellular-localized fluorescence resonance energy transfer (FRET) biosensors determined adrenergic signalling microdomains in MCs. Effects of oral rolipram, a phosphodiesterase 4 (PDE4) inhibitor, on the model were measured.</p><p><strong>Key results: </strong>Our model exhibited impaired kidney function with elevated expression of adrenergic and fibrotic genes, including Adrb1, PDEs, Acta2 and Tgfβ. RNA-seq analysis revealed that MCs with dysregulated YAP pathway were crucial to the extracellular matrix secretion in kidneys from diabetic nephropathy patients. In cultured MCs, TGF-β promoted profibrotic gene transcription, which was regulated by nuclear-localized β-adrenoceptor signalling. Mechanistically, TGF-β treatment diminished nuclear-specific cAMP signalling in MCs and reduced PKA-dependent phosphorylation of YAP, leading to its activation. In parallel, db/db mouse kidneys showed increased expressions of PDE4B and PDE4D. Treatment with oral rolipram alleviated kidney fibrosis in db/db mice.</p><p><strong>Conclusion and implications: </strong>Diabetic nephropathy impaired nuclear-localized β<sub>1</sub>-adrenoceptor-cAMP signalling microdomain through upregulating PDE4 expression, promoting fibrosis in MCs via PKA dephosphorylation-dependent YAP activation. Our results suggest PDE4 inhibition as a promising strategy for alleviating kidney fibrosis in diabetic nephropathy.</p>","PeriodicalId":9262,"journal":{"name":"British Journal of Pharmacology","volume":null,"pages":null},"PeriodicalIF":6.8000,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/bph.17347","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and purpose: Diabetic nephropathy (DN) is a leading cause of chronic kidney disease (CKD), which is characterized by mesangial matrix expansion that involves dysfunctional mesangial cells (MCs). However, the underlying mechanisms remain unclear. This study aims to delineate the spatiotemporal contribution of adrenergic signalling in diabetic kidney fibrosis to reveal potential therapeutic targets.

Experimental approach: A model of diabetic nephropathy was induced by in db/db mice. Gene expression in kidneys was profiled by RNA-seq analyses, western blot and immunostaining. Subcellular-localized fluorescence resonance energy transfer (FRET) biosensors determined adrenergic signalling microdomains in MCs. Effects of oral rolipram, a phosphodiesterase 4 (PDE4) inhibitor, on the model were measured.

Key results: Our model exhibited impaired kidney function with elevated expression of adrenergic and fibrotic genes, including Adrb1, PDEs, Acta2 and Tgfβ. RNA-seq analysis revealed that MCs with dysregulated YAP pathway were crucial to the extracellular matrix secretion in kidneys from diabetic nephropathy patients. In cultured MCs, TGF-β promoted profibrotic gene transcription, which was regulated by nuclear-localized β-adrenoceptor signalling. Mechanistically, TGF-β treatment diminished nuclear-specific cAMP signalling in MCs and reduced PKA-dependent phosphorylation of YAP, leading to its activation. In parallel, db/db mouse kidneys showed increased expressions of PDE4B and PDE4D. Treatment with oral rolipram alleviated kidney fibrosis in db/db mice.

Conclusion and implications: Diabetic nephropathy impaired nuclear-localized β1-adrenoceptor-cAMP signalling microdomain through upregulating PDE4 expression, promoting fibrosis in MCs via PKA dephosphorylation-dependent YAP activation. Our results suggest PDE4 inhibition as a promising strategy for alleviating kidney fibrosis in diabetic nephropathy.

核定位的β肾上腺素受体信号减弱会激活YAP,从而促进糖尿病肾病患者的肾脏纤维化。
背景和目的:糖尿病肾病(DN)是慢性肾病(CKD)的主要病因,其特点是间质基质扩张,涉及功能障碍的间质细胞(MCs)。然而,其潜在机制仍不清楚。本研究旨在阐明肾上腺素能信号在糖尿病肾脏纤维化中的时空贡献,以揭示潜在的治疗靶点:实验方法:用 db/db 小鼠诱导糖尿病肾病模型。通过RNA-seq分析、Western印迹和免疫染色法分析肾脏中的基因表达。亚细胞定位荧光共振能量转移(FRET)生物传感器确定了 MCs 中的肾上腺素能信号微域。测量了口服磷酸二酯酶4(PDE4)抑制剂罗利普仑对模型的影响:我们的模型表现出肾功能受损,肾上腺素能基因和纤维化基因(包括 Adrb1、PDEs、Acta2 和 Tgfβ)表达升高。RNA-seq分析显示,YAP通路失调的MCs对糖尿病肾病患者肾脏细胞外基质的分泌至关重要。在培养的 MCs 中,TGF-β 促进了组织坏死基因的转录,而这种转录受核定位的 β 肾上腺素受体信号调控。从机理上讲,TGF-β处理减少了MC细胞核特异性cAMP信号,降低了YAP的PKA依赖性磷酸化,从而导致YAP被激活。与此同时,db/db 小鼠肾脏显示出 PDE4B 和 PDE4D 的表达增加。口服罗利普仑治疗可减轻db/db小鼠的肾脏纤维化:糖尿病肾病通过上调 PDE4 的表达损害了核定位的 β1 肾上腺素受体-CAMP 信号微域,通过 PKA 去磷酸化依赖性 YAP 激活促进 MCs 纤维化。我们的研究结果表明,抑制 PDE4 是缓解糖尿病肾病肾脏纤维化的一种有效策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
15.40
自引率
12.30%
发文量
270
审稿时长
2.0 months
期刊介绍: The British Journal of Pharmacology (BJP) is a biomedical science journal offering comprehensive international coverage of experimental and translational pharmacology. It publishes original research, authoritative reviews, mini reviews, systematic reviews, meta-analyses, databases, letters to the Editor, and commentaries. Review articles, databases, systematic reviews, and meta-analyses are typically commissioned, but unsolicited contributions are also considered, either as standalone papers or part of themed issues. In addition to basic science research, BJP features translational pharmacology research, including proof-of-concept and early mechanistic studies in humans. While it generally does not publish first-in-man phase I studies or phase IIb, III, or IV studies, exceptions may be made under certain circumstances, particularly if results are combined with preclinical studies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信